We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Treatment of an Inherited Ventricular Arrhythmia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05122975
Recruitment Status : Not yet recruiting
First Posted : November 17, 2021
Last Update Posted : July 18, 2022
Food and Drug Administration (FDA)
Information provided by (Responsible Party):
Armgo Pharma, Inc.

Brief Summary:
The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48168 (ARM210) repairs these leaky channels and can be a disease-modifying therapy restoring normal function to the channels. This result would allow children and adults with CPVT to live normal, active lives. Funding Source- FDA OOPD.

Condition or disease Intervention/treatment Phase
Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 Drug: S48168 (ARM210) Drug: Matching Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: S48168 and exact matching placebo
Primary Purpose: Treatment
Official Title: Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1)
Estimated Study Start Date : October 2022
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : March 2024

Arm Intervention/treatment
Experimental: S48168 (ARM210) once daily for 28 days
Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
Drug: S48168 (ARM210)
Ryanodine Receptor modulator

Placebo Comparator: Matching Placebo once daily for 28 days
Oral dose of placebo once daily on top of standard of care regimen for 28 days.
Drug: Matching Placebo
Placebo if same size and consistency as S48168 (ARM210)

Primary Outcome Measures :
  1. The effect of S48168 (ARM210) treatment on the amount and complexity of exercise-induced ventricular ectopic beats compared to baseline in patients with CPVT1 using a novel Complexity Scale (CS) for ventricular ectopy. [ Time Frame: 28 days ]

    Analysis of ECG recordings during exercise testing examining for abnormal beats occurring with exercise, such as premature ventricular contractions (PVCs). The scale is as follows:

    1. No ventricular ectopy ZERO Points
    2. PVCs only - 1 point
    3. PVCs in bigeminy - 2 points
    4. Couplets including bidirectional couplets - 5 points
    5. 3-5 beat runs of Non-sustained ventricular tachycardia (NSVT) - 10 points
    6. > 5 beat runs of NSVT - 15 points
    7. Sustained ventricular tachycardia (VT)/ ventricular fibrillation (VF) - 20 points

    Also, add 5 points for ectopy onset at heart rate <=120; 3 points for Ectopy onset at heart rate > 120 but <= 150; 1 point for Ectopy Onset at heart rate > 150. The lower the heart rate at which ectopy occurs, the more severe the clinical phenotype is considered to be.

Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 28 days ]
    The number and severity of adverse events that can be related to treatment with S48168 (ARM210)

Other Outcome Measures:
  1. The pharmacokinetics (PK) of a 28-day administration of S48168 (ARM210) in patients [ Time Frame: 28 days ]
    Day one and day 28 maximal plasma concentration (Cmax)

  2. Total Plasma Drug Exposure of a 28-day administration of S48168 (ARM210) in patients [ Time Frame: 28 days ]
    Measurement of the area under the curve (AUC) at day 1 and day 28 in plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must meet all the following conditions to be eligible for enrollment into the study:

  1. Adult males and females, 18 - 65 years of age, inclusive, at screening; or be a male or female child age 12 and up whose weight >=50 kg.
  2. For children: be up to date on childhood vaccinations, specifically varicella vaccine (chicken pox) and Measles, Mumps & Rubella.
  3. Children's parent or legal guardian has provided written informed consent/Health Insurance Portability and Accountability Act authorization prior to any study-related procedures.
  4. Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, study restrictions, and study procedures.
  5. For adults: Body mass index (BMI) ≤ 36.0 kg/m2 at screening.
  6. Confirmed genetic diagnosis of CPVT1 and supporting clinical phenotype, including residual ventricular ectopy (i.e. a complexity score >0) on their last exercise stress test on a stable medical regimen.
  7. Must have a CYP2C8 extensive or intermediate metabolizer genotype.
  8. Daily use of medicines and dietary supplements need to be approved by the PI and Sponsor, or a drug/supplement-dependent wash-out prior to inclusion.
  9. For male subjects: is sterile or agrees to use an appropriate method of contraception, including a condom with spermicide, from study drug administration on the first day of dosing until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug administration. No restrictions are required for a vasectomized male subject provided the subject is at least 1-year post-bilateral vasectomy procedure prior to study drug administration on first day of the first dose. A male subject whose vasectomy procedure was performed less than 1 year prior to study drug administration on the first day of dosing must follow the same restrictions as a non-vasectomized male. Appropriate documentation of surgical procedure should be provided.
  10. For male subjects: agrees to not donate sperm from study drug administration on the first day of dosing until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug.
  11. For female subjects of childbearing potential: uses one of the following highly effective birth control methods (from the first dose until 5 half-lives plus 90 days (approximately 94 days):

    • Prescribed hormonal oral contraceptives, vaginal ring, or transdermal patch.
    • Intrauterine device (IUD).
    • Intrauterine hormone-releasing system (IUS).
    • Depot/implantable hormone (e.g., Depo-Provera®, Implanon).
    • Bilateral tubal occlusion/ligation.
    • Sexual abstinence:

      • Refraining from heterosexual intercourse during the entire period of risk associated with the study requirements.
      • If the participant decides to become sexually active during the study, then one of the highly effective birth control methods must be used.
  12. For female subjects of non childbearing potential; defined by at least 1 of the following criteria:

    • Postmenopausal defined as 12 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) serum level > 40mIU/mL. Appropriated documentation of FSH levels is required.
    • Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation of surgical procedure.
    • Has a congenital condition resulting in no uterus.
  13. Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and study procedures (exercise testing and PK sampling).
  14. Able to provide written informed consent or assent and understands the study procedures in the informed consent form (ICF) or assent form.

Exclusion Criteria:

The presence of any of the following conditions will exclude a patient from study enrollment:

  1. Patient is mentally or legally incapacitated at the time of the screening visit or during the conduct of the study.
  2. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose of study drug.
  3. History or presence of hypersensitivity or idiosyncratic reaction to the study drug, related compounds, or inactive ingredients.
  4. Positive urine drug or alcohol results at screening.
  5. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
  6. Patients with baseline ALT or AST levels three times above the upper limits of normal (ULN) (isolated elevations of total bilirubin <2 X ULN with direct bilirubin below the ULN will be included).
  7. Patients with a history of documented epileptic seizures (not including febrile or Stokes-Adams events, i.e. cardiovascular syncope).
  8. Subject has a history of cancer (malignancy) Exceptions: (1) Subjects with adequately treated non-melanomatous carcinoma or carcinoma in situ of the cervix may participate in the trial (2) Subjects with other malignancies who have been successfully treated > 10 years prior to the screening where in the judgment of the investigator has revealed no evidence of recurrence from the time of treatment through the time of the screening except those identified at the beginning of the exclusion criterion or (3) Subjects who in the opinion of the investigator are highly unlikely to sustain a recurrence for the duration of the trial.
  9. Patients with uncontrolled diabetes defined as HbA1c > 7% or diabetic neuropathy.
  10. Estimated creatinine clearance <40 mL/minute at screening.
  11. Patients with a clinically significant abnormality on their resting ECG other than hypertensive related, or heart failure (ejection fraction <30%) or other clinically significant structural heart disease on echocardiogram.
  12. Patients with a history of myocardial infarction in the last five years, or evidence of congestive heart failure.
  13. Pregnant and breastfeeding women.
  14. Unable to refrain from or anticipates the use of:

    • Any non-approved medicines and/or dietary supplements beginning 14 days prior to the first dose of study drug and throughout the study. Thyroid hormone replacement medication may be permitted if subject has been on same stable dose for the last 3 months prior to the first dose of study drug.
    • Any drugs known to be significant inducers or inhibitors of CYP2C8 enzymes for 28 days prior to the first dose of study drug and throughout the study. Any substrates of breast cancer resistance protein (BCRP).
  15. Is currently taking any drug which raises gastric pH, including proton pump inhibitors or H2 antagonists. Antacids may be used if taken at night.
  16. Donation of blood or significant blood loss within 56 days prior to the first dose of study drug.
  17. Plasma donation within 7 days prior to the first dose of study drug.
  18. Participation in clinical trials for other therapeutic investigational drugs simultaneously or within the 4 weeks prior to the first dose of study drug.
  19. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.
  20. is unable to take orally administered tablets.
  21. Have known allergy or intolerance to lactose, present in placebo tablets.
  22. is an immediate family member of the sponsor or employee of the clinical site or may consent under duress.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05122975

Layout table for location contacts
Contact: Eugene E Marcantonio, MD PhD 2014633634 Gmarcantonio@armgo.com

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact: Michaela J Saunders, RN       Saunders.Michaela@mayo.edu   
Principal Investigator: Michael J Ackerman, MD PhD         
Sub-Investigator: Johan M Bos, MD         
Sponsors and Collaborators
Armgo Pharma, Inc.
Food and Drug Administration (FDA)
Layout table for investigator information
Principal Investigator: Michael J Ackerman, MD PhD Mayo Clinic
Layout table for additonal information
Responsible Party: Armgo Pharma, Inc.
ClinicalTrials.gov Identifier: NCT05122975    
Other Study ID Numbers: CL2-210-01
1R01FD007279-01 ( U.S. FDA Grant/Contract )
First Posted: November 17, 2021    Key Record Dates
Last Update Posted: July 18, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Armgo Pharma, Inc.:
Ventricular Arrhythmia
Ryanodine Receptor 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia, Ventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes